Price History
Feb 9, 2026 — Feb 23, 2026Investment Snapshot
- Trading 227% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -6.2%
- Revenue growing at 19% annually
DYNAVAX TECHNOLOGIES CORP (DVAX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.8 billion . Key value metrics: P/E ratio 73.8, P/B ratio 3.41, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
DYNAVAX TECHNOLOGIES CORP — Fundamental Analysis Summary
DYNAVAX TECHNOLOGIES CORP (DVAX) is currently trading 227% above its Graham Number of $4.74, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 73.8x.
On financial health, DVAX shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -6.2% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.77.
StockPik's composite Value Score for DVAX is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DVAX shows revenue growing at 19% year-over-year, with earnings growing at 527%.